Compare Johnson & Johnson (JNJ) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance

Johnson & JohnsonTrade

Royalty Pharma plc Class A Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Johnson & Johnson is far larger — about 24.5× Royalty Pharma plc Class A Ordinary Shares's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.

	JNJ	RPRX
Market Cap	$618.09B	$25.27B
Volume	6,050,983	3,671,183
Sector	Health	Health
52-Week High	$278.43	$63.96
52-Week Low	$186.00	$35.44
Typical Hold Time	129 Days	1 Days
Enterprise Value	$646.37B	$32.50B
Dividend Yield	2.09%	1.66%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).

JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.

Royalty Pharma plc Class A Ordinary Shares

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JNJ

82% Buy18% Sell

Avg holding period · 129 Days

RPRX

No sentiment data available yet.

Top news

Latest headlines on both assets

JNJ

Johnson & Johnson Q3 earnings expected with 5% EPS drop but 5.8% revenue growthGordon Thompson · 14 hours agoNeutral Four Dividend Kings remain strong but PepsiCo's dividend payout is riskier than others.24/7 Wall Street · 17 hours agoNeutral New Phase 3 data show ICOTYDE provides lasting skin clearance in moderate-to-severe plaque psoriasis over two years.PRNewsWire · 18 hours agoBullish View details →

RPRX

Royalty Pharma to release Q3 2026 earnings on Nov 4 with live webcast and call.GlobeNewsWire · 17 hours agoNeutral View details →

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

About Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.